Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Becton, Dickinson and Company. A complete text table follows the diagram.
After combining its diagnostics and biosciences business with Waters, BD is now concentrated around medication delivery, connected care and intervention.
Swipe to explore
The diagram depicts BD's continuing operating portfolio after the February 9, 2026 spin-off. Segment operating income excludes corporate, transaction, restructuring, purchase-accounting and other unallocated items defined in the filing. Rounded segment amounts sum to $1,725 million although the reported total line is $1,724 million.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Medical essentials | 1 | $1.6B | Medication delivery & specimen collection |
| Connected care | 1 | $1.1B | Medication systems & patient monitoring |
| BioPharma systems | 1 | $590M | Drug-delivery components for manufacturers |
| Interventional | 1 | $1.4B | Vascular, urology & surgical products |
| Essentials operating income | 2 | $574M | 34.8% segment margin |
| Essentials product engine | 2 | $1.1B | Manufacturing, selling and R&D |
| Connected Care operating income | 2 | $347M | 31.0% segment margin |
| Connected Care product engine | 2 | $773M | Hardware, software, selling and R&D |
| BioPharma operating income | 2 | $225M | 38.1% segment margin |
| BioPharma product engine | 2 | $365M | Drug-delivery manufacturing and support |
| Interventional operating income | 2 | $579M | 42.7% segment margin |
| Interventional product engine | 2 | $778M | Devices, selling and clinical innovation |
| From | To | Value |
|---|---|---|
| Medical essentials | Essentials operating income | $574M |
| Medical essentials | Essentials product engine | $1.1B |
| Connected care | Connected Care operating income | $347M |
| Connected care | Connected Care product engine | $773M |
| BioPharma systems | BioPharma operating income | $225M |
| BioPharma systems | BioPharma product engine | $365M |
| Interventional | Interventional operating income | $579M |
| Interventional | Interventional product engine | $778M |